Tumor microenvironment (TME) has been regarded as a critical regulating environment for immune response and tumor growth in recent years. Similar to the interaction between seeds and soil, TME ...
Dawn portrays shadows and fleeting openings in the heavy fog. First awake, inquisitive eyes attempt to pierce the grayness, searching out a stepping stone secure enough to settle on next. "There it is ...
Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune-mediated destruction of pancreatic B cells. While autoreactive T cells are key ...
T-bet expression is required for persistence of memory B cells that have rapid differentiation potential to become antibody-producing plasma cells in response to a second infection BIRMINGHAM, Ala. – ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
Zenas BioPharma announced advancements in the clinical development of obexelimab, a novel CD-19 x FcγRIIb inhibitor targeting B cell function, with key trial results expected in 2025. The Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results